ArticleNPJ breast cancer2019

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.

Mellissa J Nixon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.